1. A method of treating a subject having a wound not healing at an expected rate, comprising administering to the wound a composition comprising an anti-connexin 43 polynucleotide and a pharmaceutically acceptable carrier, wherein the amount of said anti-connexin 43 polynucleotide administered to said wound ranges from about 30 to about 500 \u03bcg per square centimeter of said wound.
2. A method according to claim 1, wherein the amount of anti-connexin 43 polynucleotide administered ranges from about 50 to about 500 \u03bcg per square centimeter of said wound.
3. A method according to claim 1, wherein the amount of anti-connexin 43 polynucleotide administered ranges from about 100 to about 500 \u03bcg per square centimeter of said wound.
4. A method according to claim 1, wherein the amount of anti-connexin 43 polynucleotide administered ranges from about 150 to about 500 \u03bcg per square centimeter of said wound.
5. A method according to claim 1, wherein the amount of anti-connexin 43 polynucleotide administered ranges from about 200 to about 500 \u03bcg per square centimeter of said wound.
6. A method according to claim 1, wherein the amount of anti-connexin 43 polynucleotide administered ranges from about 250 to about 500 \u03bcg per square centimeter of said wound.
7. A method according to claim 1, wherein the amount of anti-connexin 43 polynucleotide administered ranges from about 100 to about 250 \u03bcg per square centimeter of said wound.
8. A method according to claim 1, wherein the amount of anti-connexin 43 polynucleotide administered ranges from about 100 to 200 \u03bcg per square centimeter of said wound.
9. A method of treating a subject having a wound not healing at an expected rate, which comprises administering to the wound a composition comprising a pharmaceutically acceptable carrier and an anti-connexin 43 polynucleotide present in a concentration range of about 30 \u03bcM to about 200 \u03bcM.
10. A method according to claim 9 wherein said anti-connexin 43 polynucleotide is present in a concentration range of about 30 \u03bcM to about 100 \u03bcM.
11. A method according to claim 9 wherein said anti-connexin 43 polynucleotide is present in a concentration range of about 30 \u03bcM to about 50 \u03bcM.
12. A method according to claim 9 wherein said anti-connexin 43 polynucleotide is present in a concentration of about 100 \u03bcM.
13. A method according to claim 1 wherein the pharmaceutically acceptable carrier comprises a polyoxyethylene-polyoxypropylene copolymer.
14. A method according to claim 1 wherein the pharmaceutically acceptable carrier comprises Pluronic F-127.
15. A method according to claim 1 wherein the pharmaceutically acceptable carrier comprises an alginate.
16. A method according to claim 1 wherein the pharmaceutically acceptable carrier comprises a hydrogel.
17. A method according to claim 1 wherein the pharmaceutically acceptable carrier comprises a hydrogel selected from the group consisting of hydrogels containing a cellulose derivative and hydrogels containing polyacrylic acid.
18. A method according to claim 1 wherein the pharmaceutically acceptable carrier is a cellulose-based carrier.
19. A method according to claim 1 wherein the pharmaceutically acceptable carrier comprises a cellulose-based carrier selected from the group consisting of hydroxyethyl cellulose, hydroxymethyl cellulose, carboxymethyl cellulose, hydroxypropylmethyl cellulose and mixtures thereof.
20. A method according to claim 1 wherein the composition is formulated for sustained release.
21. A method according to claim 1 wherein the composition is formulated for slow release, extended release, or controlled release.
22. A method according to claim 1 wherein the composition is a gel.
23. A method according to claim 1 wherein the composition is a cream, ointment, emulsion, lotion, spray, salve, foam or paint.
24. A method according to claim 1 wherein the wound is characterized at least in part by increased expression of connexin 43.
25. A method according to claim 1 wherein the wound is characterized at least in part by inflammation.
26. A method according to claim 1 wherein the wound is a delayed or incompletely healing wound.
27. A method according to claim 1 wherein the wound is a dehiscent wound.
28. A method according to claim 1 wherein the wound is a chronic wound.
29. A method according to claim 1 wherein the wound is a chronic wound characterized at least in part by inflammation.
30. A method according to claim 1 wherein the wound is a venous ulcer.
31. A method according to claim 1 wherein the wound is an arterial ulcer.
32. A method according to claim 1 wherein the wound is a pressure ulcer.
33. A method according to claim 1 wherein the wound is a diabetic ulcer.
34. A method according to claim 1 wherein the wound is a vasculitic ulcer.
35. A method according to claim 1 wherein the wound is a skin ulcer resulting from trauma or a burn.
36. A method according to claim 1 wherein the wound is a non-healing wound.
37. A method according to claim 1 wherein the subject is diabetic.
38. A method according to claim 1 wherein the subject has peripheral neuropathy.
39. A method according to claim 1 wherein the subject has a venous valve malfunction andor venous insufficiency.
40. A method according to claim 1 wherein the subject has an arterial blockage.
41. A method according to claim 1 wherein said composition is applied more than once.
42. A method according to claim 1 wherein the administration of said composition is repeated about once per week.
43. A method according to claim 1 wherein said polynucleotide has from about 18 to about 32 nucleotides.
44. A method according to claim 1 wherein the anti-connexin 43 polynucleotide is an oligodeoxynucleotide.
45. A method according to claim 9 wherein the anti-connexin 43 polynucleotide is an oligodeoxynucleotide.
46. A method according to claim 1 wherein the anti-connexin 43 polynucleotide is a modified oligodeoxynucleotide.
47. A method according to claim 1 wherein the anti-connexin 43 polynucleotide is an unmodified oligodeoxynucleotide.
48. A method according to claim 1 wherein the anti-connexin 43 polynucleotide is a connexin 43 antisense polynucleotide.
49. A method according to claim 1 wherein the anti-connexin 43 polynucleotide is an unmodified connexin 43 antisense polynucleotide.
50. A method according to claim 1 wherein the anti-connexin 43 polynucleotide is an antisense polynucleotide comprising a sequence selected from SEQ ID NOS: 1 or 2.
51. A method according to claim 1 wherein the anti-connexin 43 polynucleotide is an antisense polynucleotide having at least about 70 percent homology with SEQ ID NOS: 1 or 2.
52. A method according to claim 1 wherein the anti-connexin 43 polynucleotide is an antisense polynucleotide that hybridizes to connexin 43 mRNA under conditions of medium to high stringency.
53. A method according to claim 44 wherein the oligodeoxynueleotide is a modified oligodeoxynucleotide.
54. A method according to claim 44 wherein the oligodeoxynucleotide is an unmodified oligodeoxynucleotide.
55. A method according to claim 1 wherein the subject is a human.
56. A method according to claim 1 wherein the subject is a non-human animal.
57. A method according to claim 56 wherein the non-human animal is selected from the group consisting of farm animals, zoo animals, sports animals, and pet animals.
58. A method according to claim 56 wherein the non-human animal is a horse, a dog or a cat.
59. A method according to claim 1 wherein the anti-connexin 43 polynucleotide is an RNAi or siRNA polynucleotide.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A system for storing golf balls on a waist of a wearer including a pocket of a longitudinal extent having ends and locating said pocket in a horizontal manner and having means for mounting said pocket on a waist band of said wearer, said pocket is constructed of a flexible and stretchable material to snugly hold a multiple of balls within said pocket, said balls may be dispensed one at a time including means for mounting said pocket on said waist band of said wearer, wherein said waist band has placed therein at least two double slits spaced from each other, including a single strap attached to a back side of said pocket to thereby create an end of said strap on each end of said pocket, two double D-rings are each located at each end of said pocket, whereby, when each end of said strap is threaded through each of said double D-rings, each of said ends is received within said D-rings and locked therein after having been passed through said double slits.
2. The system of claim 1 including means for storing golf related items in said pocket.
3. The system of claim 1 including a separable closure located at a top edge of said pocket.
4. The system of claim 3, wherein side edges of said pocket are closed to thereby form a completely closed pocket.